Business Wire

MA-NETCRACKER-TECHNOLOGY

3.6.2020 14:02:09 CEST | Business Wire | Press release

Share
Netcracker 2020 Puts Service Providers at the Center of the Digital Economy

Netcracker Technology announced today the launch of its Netcracker 2020 portfolio to help service providers focus on their customer’s digital lifestyle. With Netcracker 2020 , service providers can transform customer engagement, dynamically evolve their digital ecosystems and reach new levels of automation and security, helping them to innovate and disrupt in the 5G digital economy.

Netcracker 2020 Digital BSS /OSS and Customer Engagement products and services have been redesigned and enhanced for the 5G era. The new digital portfolio is fully open and standards compliant, built for the cloud and allows service providers to develop their own enhancements or co-develop functions through a low code platform and blueprint delivery approach. With continuous short releases using Agile/DevOps processes, service providers gain faster access to innovative features with no disruptions to business operations. Central to Netcracker 2020 is an industry-leading security framework, designed to provide the highest level of proven system-wide security and privacy, which is critical in an era of increased cyber-attacks, intrusion and disruption.

In addition, as the world prepares for the uncertainty of a post COVID-19 environment, service providers want to increase the effectiveness of remote consumer and business interactions. With Netcracker 2020, they can radically transform customer engagement by anticipating their needs using AI-driven contextual interactions that go beyond problem solving and deliver relevant new services that combine service providers’ own services with those from partners and enriched with 5G experiences. As customers’ requirements become even more of a priority for service providers, personalized offerings can be dynamically created and delivered with a ground-breaking gaming-style user experience and cross-partner loyalty schemes.

Evolving to a more partner-based digital economy will require management of complex relationships, interconnections and business models with new and constantly changing partners, including other service providers. Netcracker 2020 helps build dynamic digital ecosystems that quickly adapt to changing business and market needs. With automated onboarding, simplified lifecycle management and partner-centric B2B2X opportunities, service providers will become both leaders and enablers of new platform-based monetization opportunities in diverse markets.

As services, networks and partnerships become more complex, full automation at every level has become a necessity. Netcracker 2020 uses a new operational model to remove manual tasks and drive hyper automation across network domains, services that cross domains, business processes and channels that are quickly moving towards open 5G networks with cloud-native functions and highly demanding edge cloud applications. Netcracker 2020 digital applications are cloud-native and designed to run in a multicloud environment, delivering the same high performance and resiliency on public clouds as on-premise cloud platforms. This also includes a security architecture and trust center that has become the industry benchmark.

“As BSS/OSS becomes increasingly critical to assure customer experience and enable security and flexible services, Netcracker has strengthened its position as the leader in helping service providers succeed in the highly competitive digital economy,” noted Sue Rudd, Director Networks and Service Platforms at Strategy Analytics. “Netcracker 2020 offers service providers a highly automated, multi-vendor microservices based environment to address their customers’ dynamic digital needs and sets the benchmark for modern BSS/OSS to accelerate revenue-generating service delivery in today’s uncertain world.”

“Netcracker 2020 is the culmination of over 25 years of experience of providing and operating mission-critical systems to hundreds of service providers around the globe in order to keep their businesses moving forward,” said Bob Titus, Chief Technology Officer, Netcracker. “This includes support for new business models, hyper automation, cloud adoption and the use of open source, outcome-based delivery models and, perhaps most importantly, an exceptional digital-first customer experience.”

About Netcracker Technology
Netcracker Technology, a wholly owned subsidiary of NEC Corporation, offers mission-critical digital transformation solutions to service providers around the globe. Our comprehensive portfolio of software solutions and professional services enables large-scale digital transformations, unlocking the opportunities of the cloud, virtualization and the changing mobile ecosystem. With an unbroken service delivery track record of more than 25 years, our unique combination of technology, people and expertise helps companies transform their networks and enable better experiences for their customers.

For more information, visit www.netcracker.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye